Advertisement

Picture EBD Group BIO-Europe Spring 2025 Milan to 28 Feb 650x100px
Document › Details

Touchlight Genetics Ltd.. (7/6/22). "Press Release: Touchlight Signs Patent License Agreement with Pfizer for the Use of dbDNA for the Manufacture of mRNA-based Vaccines, Therapeutics and Gene Therapies". Hampton.

Organisations Organisation Touchlight (Group)
  Organisation 2 Pfizer Inc. (NYSE: PFE)
  Group Pfizer (Group)
Products Product dbDNA™ (doggybone DNA)
  Product 2 mRNA-based vaccine
Persons Person Ohlson, Jonny (Touchlight Genetics 201606 CEO)
  Person 2 Bodicoat, Robin (Touchlight 202207 Head of Marketing before 201711 Marketing Director at Quotient Sciences)
     


> Pfizer and Touchlight agree to patent license for Pfizer to utilise rapid, scalable, enzymatic doggybone DNA (dbDNA) in Pfizer’s clinical and commercial manufacture of its mRNA vaccines, therapeutics, and gene therapies

> Agreement includes upfront payment, potential development and commercial milestone payments, and royalties upon commercialization

> Access to dbDNA patent rights enables Pfizer’s rapid production of DNA template as starting materials for mRNA-based vaccines and other therapeutics


Touchlight, a biotechnology company pioneering enzymatic DNA production to enable the genetic medicine revolution, today announces a non-exclusive patent license agreement with Pfizer.

Under the license agreement, Pfizer gains rights to Touchlight’s enzymatic doggybone DNA (dbDNA™) patent portfolio for worldwide use in Pfizer’s manufacture and commercialisation of its messenger RNA-based vaccines, therapeutics and gene therapies. Touchlight will receive an upfront payment, as well as clinical and commercial milestone payments and royalties upon commercialisation.

Touchlight’s patented dbDNA technology produces a minimal, linear, double stranded, covalently closed DNA vector through an enzymatic manufacturing process. dbDNA is uniquely positioned for the rapid, synthetic, and scalable manufacture of GMP DNA using a small, simple footprint. The technology can manufacture genes >20kb and accommodate sequences typically unstable as plasmid DNA in E. coli, such as those found in viral vector and mRNA production. In addition to mRNA vaccines, it is ideally suited for the development of DNA vaccines, advanced therapies, and more.

Jonny Ohlson, Founder and Executive Chair, Touchlight, commented: “We are delighted to establish this agreement with Pfizer to license our mRNA manufacturing platform. This agreement is an example of our technology’s potential to enable companies across the genetic medicine sector to simplify and accelerate DNA manufacturing through the clinic and towards commercialisation.”

Financial terms are not disclosed.


- ENDS -


About Touchlight

Touchlight is a privately-owned biotechnology company based in London, U.K., focussed on the discovery and development of DNA-based genetic medicines, including DNA vaccines and gene therapies. Touchlight has developed a novel, synthetic DNA vector known as “doggybone DNA” or dbDNA™.

dbDNA™ is a minimal, linear, covalently closed structure, that eliminates bacterial sequences. Touchlight’s revolutionary enzymatic production platform enables unprecedented speed, scale, and the ability to target genes with a size and complexity that is impossible with current technologies.

Touchlight is applying dbDNA across advanced therapeutic modalities, both in-house and with partners. The company also provides contract manufacturing capabilities to produce dbDNA as a critical starting material for advanced therapy production through its manufacturing arm, Touchlight DNA Services.


Issued for and on behalf of Touchlight by Instinctif Partners.


For more information please contact:

Jonny Ohlson, CEO
Robin Bodicoat, Head of Marketing
E: [email protected]
T: +44 20 8481 9200

Tim Watson
Agnes Stephens
E: [email protected]
T: +44 20 7457 2020

   
Record changed: 2023-06-05

Advertisement

Picture Berlin Partner Top News Aignostics Mayo Clinic Pathology 650x200px

More documents for Touchlight (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture Swiss Biotech Association LSE Swiss Biotech Days 2025 Basel 650x300px




» top